These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Batten disease: past, present, and future. Rider JA; Rider DL Am J Med Genet Suppl; 1988; 5():21-6. PubMed ID: 3146319 [TBL] [Abstract][Full Text] [Related]
47. Natural history variations for neuronal ceroid lipofuscinosis type 2: In support of newborn screening. Cabassa Miskimen A; Cohen LL; Yozawitz EG; Grinspan ZM Epilepsia; 2023 May; 64(5):1403-1404. PubMed ID: 36780254 [No Abstract] [Full Text] [Related]
48. Juvenile Batten disease: A diagnostic conundrum. Niederer K JAAPA; 2021 Jun; 34(6):44-47. PubMed ID: 34031314 [TBL] [Abstract][Full Text] [Related]
49. Prenatal diagnosis of the neuronal ceroid lipofuscinoses. Kleijer WJ; van Diggelen OP Prenat Diagn; 2000 Oct; 20(10):819-21. PubMed ID: 11038460 [No Abstract] [Full Text] [Related]
50. An EcoRI RFLP in human phenol sulfotransferase genes. Henkel RD; Galindo LV; Dooley TP Hum Mol Genet; 1994 Dec; 3(12):2264. PubMed ID: 7881437 [No Abstract] [Full Text] [Related]
51. Measuring to improve: a new rating scale for Batten disease. Patterson MC Neurology; 2011 Nov; 77(20):1779-80. PubMed ID: 22013177 [No Abstract] [Full Text] [Related]
52. Development of new treatments for Batten disease. Mole SE Lancet Neurol; 2014 Aug; 13(8):749-51. PubMed ID: 24997881 [No Abstract] [Full Text] [Related]
53. Contribution of patient organisations to the NCLs. Band H; Stehr F; Murphy N Biochim Biophys Acta Mol Basis Dis; 2020 Sep; 1866(9):165773. PubMed ID: 32224155 [TBL] [Abstract][Full Text] [Related]
54. Batten disease: current understanding and future directions. Maria BL J Child Neurol; 2013 Sep; 28(9):1072-3. PubMed ID: 23838028 [No Abstract] [Full Text] [Related]
55. Rapid and Progressive Regional Brain Atrophy in CLN6 Batten Disease Affected Sheep Measured with Longitudinal Magnetic Resonance Imaging. Sawiak SJ; Perumal SR; Rudiger SR; Matthews L; Mitchell NL; McLaughlan CJ; Bawden CS; Palmer DN; Kuchel T; Morton AJ PLoS One; 2015; 10(7):e0132331. PubMed ID: 26161747 [TBL] [Abstract][Full Text] [Related]
56. Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease. Kovács AD; Saje A; Wong A; Szénási G; Kiricsi P; Szabó E; Cooper JD; Pearce DA Neuropharmacology; 2011; 60(2-3):405-9. PubMed ID: 20971125 [TBL] [Abstract][Full Text] [Related]
57. Cln6 mutants associated with neuronal ceroid lipofuscinosis are degraded in a proteasome-dependent manner. Oresic K; Mueller B; Tortorella D Biosci Rep; 2009 Jun; 29(3):173-81. PubMed ID: 18811591 [TBL] [Abstract][Full Text] [Related]
58. Normal ascorbic acid in cerebrospinal fluid of patients with infantile neuronal ceroid-lipofuscinosis. Sass JO; Skladal D; Brunner-Krainz M Metab Brain Dis; 1999 Mar; 14(1):67-70. PubMed ID: 10348315 [TBL] [Abstract][Full Text] [Related]